$8 Billion Risperdal Judgment Reduced to $6.8 Million

The judge presiding over a case which saw Johnson & Johnson hit with an $8bn jury verdict has reduced the amount the company has to pay in damages to $6.8m.

Last October,  J&J was ordered to pay $8bn in damages to a US man who claims he was not warned that taking the company’s antipsychotic Risperdal could lead to breast growth.

A jury in Philadelphia agreed with the allegation that J&J’s Janssen unit had downplayed the risk that use of Risperdal (risperidone) in male children can cause enlarged breasts, a condition known as gynaecomastia.

About TriMark

TriMark Legal Funding provides Risperdal pre settlement funding to injured plaintiffs nationwide.

This post originally appeared here: https://www.pmlive.com/pharma_news/updated_j_and_js_$8bn_risperdal_judgment_reduced_to_$6.8m_1312458

Click here to see the full original article.